This dual role, following an initial inflammatory insult, underscores the potential for therapeutically targeting the cAMP–Epac1 axis to accelerate endogenous barrier restoration in acute vascular injury, sepsis, and ischemia–reperfusion syndromes. The gene discussed is RAPGEF3; the disease is Sepsis.